PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTrospium
Trospium
Cobenfy, Trospium (trospium) is a small molecule pharmaceutical. Trospium was first approved as Sanctura on 2004-05-28. It is used to treat overactive urinary bladder and urge urinary incontinence in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Trospium (discontinued: Sanctura, Trospium)
Combinations
Cobenfy
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trospium chloride
Tradename
Company
Number
Date
Products
SANCTURA XRAllerganN-022103 DISCN2007-08-03
1 products, RLD
SANCTURAAllerganN-021595 DISCN2004-05-28
1 products, RLD
Hide discontinued
Trospium chloride
+
Xanomeline tartrate
Tradename
Company
Number
Date
Products
COBENFYBristol Myers SquibbN-216158 RX2024-09-26
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
cobenfyNew Drug Application2024-09-30
trospium chlorideANDA2024-12-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
overactive urinary bladderEFO_1000781D053201N32.81
urge urinary incontinenceEFO_0006865D053202N39.41
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A03: Drugs for functional gastrointestinal disorders
— A03D: Antispasmodics in combination with analgesics
— A03DA: Synthetic anticholinergic agents in combination with analgesics
— A03DA06: Trospium and analgesics
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04B: Urologicals
— G04BD: Drugs for urinary frequency and incontinence
— G04BD09: Trospium
HCPCS
No data
Clinical
No data
Drug
General
Drug common nameTrospium
INNtrospium chloride
Description
Trospium chloride is a muscarinic antagonist used to treat overactive bladder. It has side effects typical of this class of drugs, namely dry mouth, stomach upset, and constipation; these side effects cause problems with people taking their medicine as directed. However it doesn't cause central nervous system side effects like some other muscarinic antagonists. It is in pregnancy category C and is excreted in breast milk.
Classification
Small molecule
Drug classquaternary ammonium derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=C(O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1
Identifiers
PDB—
CAS-ID47608-32-2
RxCUI—
ChEMBL IDCHEMBL1888176
ChEBI ID—
PubChem CID107979
DrugBankDB00209
UNII ID1E6682427E (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Trospium
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use